Higher Dose Semaglutide: What Moving Up the Schedule Actually Means

Why the schedule exists, and what it's asking your prescriber to judge

Semaglutide works by activating GLP-1 receptors involved in appetite signalling and gastric emptying. Starting low and going slowly isn't just convention: it gives your gut time to adapt and makes the side-effect profile more manageable. Most people find the early doses (0.25 mg and 0.5 mg) produce relatively modest appetite change alongside whatever GI adjustment is happening. The therapeutic weight-loss effects build as the dose climbs.

What your prescriber is looking for before approving a step up: that you've completed the minimum period at your current dose, that side effects are tolerable rather than persistent or severe, and that your weight trajectory justifies continuing. If nausea is still significant at week three of a given dose, moving up is usually delayed rather than rushed. That's not a setback, it's the titration working as designed.

You can read a full breakdown of how the semaglutide dose schedule maps across the treatment course on its own page. The short version: patience at each rung tends to produce better tolerability at the next one.

The 7.2 mg approval, what changed and who it's for

For years, 2.4 mg was the ceiling. That changed on 14 April 2026, when the MHRA approved a dedicated 7.2 mg single-dose pen, one pre-set weekly injection, with an auto-dosing mechanism and built-in covered needle that locks after use. The MHRA's announcement confirmed this is licensed for adults with a BMI of 30 or above; it is not approved for lower BMI ranges or for the cardiovascular-risk indication.

Trial data presented alongside the approval reported around 20.7% average weight loss over 72 weeks at 7.2 mg, closing the gap with the results seen for tirzepatide at higher doses in head-to-head data. If you want a closer look at what high dose semaglutide involves and how those outcomes are understood clinically, that's covered in full on its own page. That figure doesn't automatically apply to every patient; individual response varies, and the 7.2 mg dose still has to be reached through the same titration steps, not prescribed from the outset.

If you're already established on the current higher-dose Wegovy pathway at 2.4 mg and wondering whether 7.2 mg is appropriate for you, that question belongs in a prescriber review. What specific dose availability looks like at any given time is confirmed at consultation, not assumed in advance.

When a prescriber might hold the dose, or not increase it at all

Moving to a higher dose of semaglutide isn't always the right direction. NICE's guidance on semaglutide (TA875) notes that if less than 5% weight loss has occurred after six months on the maintenance dose, the clinical case for continuing (let alone increasing) needs to be reviewed. That's a useful benchmark: dose alone doesn't override an insufficient response.

There are also situations where the prescriber holds rather than advances. Persistent vomiting, signs of gallbladder problems, or severe abdominal pain that radiates to the back are reasons to pause and get medical advice urgently rather than push through to the next step. The NHS semaglutide medicines page lists the full side-effect profile worth knowing before any increase.

A common question at this stage is whether you can start semaglutide at a higher dose rather than working through the earlier steps, and the answer depends on factors your prescriber will assess individually. The pattern is similar but the intensity can differ between individuals.

Oral semaglutide follows its own separate escalation schedule (1.5 mg through to the 25 mg maintenance tablet) covered in detail on the Wegovy treatment page. If you're considering switching from injection to tablet, or vice versa, that's a clinical conversation rather than a self-managed swap.

What this means if you're buying through a private pharmacy

Private prescribing doesn't shortcut the clinical review that a dose increase requires. At a GPhC-registered pharmacy, every repeat (including one that steps you to a higher dose) is reviewed by a prescriber before it's dispensed. If you're transferring from another provider and want to continue at your existing dose, you'll need to provide evidence of current treatment; the same applies before any increase is approved.

Some people come to a private route because NHS waiting lists for specialist weight management services are long. That's a reasonable decision, provided the pharmacy you use is verifiable. You can check any online pharmacy on the GPhC register in under a minute, worth doing before handing over personal health information or payment details. A quick look before the school run takes less time than the search that brought you here.

Understanding your Wegovy dose options in full, and what reaching the higher end of the schedule realistically involves, makes the consultation more productive. Our clinical team reviews every case personally; if a higher semaglutide dose is clinically appropriate, that decision gets made with you, not for you.

If you'd like to explore whether semaglutide is right for you at any dose, start your free consultation and a GPhC-registered prescriber will review your case the same day.